Skip to content

An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients

An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02878980
Enrollment
0
Registered
2016-08-25
Start date
2016-09-02
Completion date
2018-12-31
Last updated
2018-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Carcinoma

Brief summary

This clinical trial studies how well an exercise intervention works in reducing symptoms and improving clinical outcomes in patients with ovarian cancer undergoing platinum-based chemotherapy. Exercise may train the body to repair deoxyribonucleic acid (DNA) damage more efficiently, which may reduce symptoms related to platinum-based chemotherapy, improve quality of life, increase survival, and decrease recurrence rates in patients with ovarian cancer.

Detailed description

PRIMARY OBJECTIVES: I. To assess the feasibility of recruiting and enrolling newly diagnosed epithelial ovarian cancer patients who have undergone debulking surgery and will be starting platinum-based chemotherapy, to an exercise trial. II. To evaluate adherence to the data collection and exercise trial protocol. It is necessary to determine the feasibility of collecting tablet-based questionnaire data and blood samples at multiple time points in one visit. It is also critical to determine whether the exercise intervention is feasible in this patient population. SECONDARY OBJECTIVES: I. To examine changes in DNA repair function before and after a single exercise session. II. To examine changes in DNA repair function, body composition, quality of life, symptoms and patient satisfaction with care over the treatment time course. III. To examine the effect of the exercise intervention on these measurements. IV. To follow the patients an additional 12-months for clinical outcomes defined as death, cancer recurrence, or new primary cancer. OUTLINE: Patients undergo supervised 1-on-1 exercise sessions for 60 minutes on day 1.Treatment repeats every 3 weeks for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive a home-based exercise prescription including instructions for keeping patients' heart rate within 50-80% maximum. After completion of study, patients are followed up for 12 months.

Interventions

OTHERQuestionnaire Administration

Ancillary studies

BEHAVIORALExercise Intervention

Undergo supervised 1-on-1 exercise sessions

OTHERLaboratory Biomarker Analysis

Correlative studies

OTHERQuality-of-Life Assessment

Ancillary studies

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
City of Hope Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Women who have been newly diagnosed with a first primary, epithelial ovarian cancer, have undergone surgical debulking and who will be treatment according to the Armstrong method * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately. * Newly diagnosed, primary, epithelial ovarian cancer * Have undergone surgical debulking * Will be treated according to the Armstrong method * Read and understand English * All subjects must have the ability to understand and the willingness to sign a written informed consent

Exclusion criteria

* Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Design outcomes

Primary

MeasureTime frame
Adherence to the data collection and exercise trial protocol, defined as the number of sessions attended, questionnaires completed, and blood samples completed18 weeks
Feasibility of recruiting and enrolling patients to an exercise trial, defined as the number of people contacted, eligible consented and enrolled12 months

Secondary

MeasureTime frameDescription
Change in body compositionBaseline to 18 weeksWill be analyzed using paired t-tests. Data from women in course 1 will be compared to data in women in course 6.
Change in DNA repair function, assessed by host reactivation assaysBefore single exercise session to after single exercise session, assessed up to 12 monthsWill be analyzed using paired t-tests
Change in quality of life, assessed by questionnairesBaseline to 18 weeksWill be analyzed using paired t-tests. Data from women in course 1 will be compared to data in women in course 6.
Change in symptoms, assessed by National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 version 2Baseline to 18 weeksWill be analyzed using paired t-tests. Data from women in course 1 will be compared to data in women in course 6.
Change in treatment satisfaction, assessed by Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-GeneralBaseline to 18 weeksWill be analyzed using paired t-tests. Data from women in course 1 will be compared to data in women in course 6.
Clinical outcome follow-up defined as death, cancer recurrence, or new primary cancerUp to 12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026